Asymptomatic gastrointestinal carriage of multidrug-resistant carbapenemase-producing Enterobacteriaceae among children under five years in a Kenyan hospital.
Carbapenem-producing Enterobacteriaceae
Carbapenem-resistant Enterobacteriaceae
Gastrointestinal carriage
Multidrug-resistant
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
29
06
2023
revised:
26
07
2023
accepted:
29
07
2023
medline:
11
10
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
Asymptomatic gastrointestinal carriage of carbapenem-resistant Enterobacteriaceae (CRE) is a threat to global health in developing countries with inadequate safe drinking water, poor hygiene, and weak antimicrobial stewardship; however, epidemiological data to guide CRE infection prevention and control is limited in these settings. We assessed asymptomatic CRE and carbapenem-producing Enterobacteriaceae (CPE) fecal carriage rates and associated risk factors among hospitalized children aged under 5 years. We adopted a cross-sectional study at Mama Lucy Kibaki Hospital in Nairobi-City County, Kenya, between June and September 2022. We collected demographic and clinical characteristics using a structured questionnaire and clinical reports and analyzed stool/rectal swab samples by standard and automated bacteriological methods. Asymptomatic CRE and CPE fecal carriage rate was 2.25% (6/267), with six isolates recovered, predominated by Asymptomatic gastrointestinal carriage of multidrug-resistant-CRE among hospitalized children under 5 years, presents a substantial public health threat. This calls for continuous surveillance including molecular characterization of isolates, to inform infection prevention and antimicrobial stewardship adherence in line with local and global plans on AMR.
Identifiants
pubmed: 37818227
doi: 10.1016/j.ijregi.2023.07.007
pii: S2772-7076(23)00077-2
pmc: PMC10561037
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-31Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
BMC Infect Dis. 2022 Nov 22;22(1):877
pubmed: 36418990
Front Med (Lausanne). 2021 Jan 26;8:615649
pubmed: 33575265
Front Microbiol. 2018 Oct 30;9:2391
pubmed: 30425686
J Clin Med Res. 2022 Jul;14(7):251-259
pubmed: 35974805
Ann Clin Microbiol Antimicrob. 2023 Jan 29;22(1):10
pubmed: 36710337
Ther Adv Infect Dis. 2016 Feb;3(1):15-21
pubmed: 26862399
Ann Clin Microbiol Antimicrob. 2017 Mar 29;16(1):18
pubmed: 28356109
Microb Drug Resist. 2019 Jul/Aug;25(6):839-845
pubmed: 30835635
Infect Drug Resist. 2020 Dec 10;13:4405-4415
pubmed: 33328745
Infect Drug Resist. 2022 Apr 06;15:1601-1611
pubmed: 35418762
Biomed Res Int. 2021 Jun 11;2021:9999638
pubmed: 34195291
Int J Mol Sci. 2018 Jul 30;19(8):
pubmed: 30061509
Am J Infect Control. 2016 Feb;44(2):126-30
pubmed: 26631643
Front Microbiol. 2021 Oct 06;12:740348
pubmed: 34690985
Antimicrob Resist Infect Control. 2017 Jan 11;6:10
pubmed: 28096978
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575
pubmed: 31724043
Clin Infect Dis. 2020 Dec 3;71(9):e478-e486
pubmed: 32060523
PLoS One. 2016 Jan 29;11(1):e0147363
pubmed: 26824353
PLoS One. 2015 Aug 18;10(8):e0135745
pubmed: 26284519
Front Microbiol. 2019 Jan 31;10:44
pubmed: 30766518
BMC Infect Dis. 2019 Aug 1;19(1):678
pubmed: 31370804
Med Sci (Basel). 2017 Dec 21;6(1):
pubmed: 29267233
Infect Drug Resist. 2019 Apr 24;12:965-975
pubmed: 31190901
PLoS One. 2022 Apr 14;17(4):e0264559
pubmed: 35421129
PLoS One. 2016 Aug 30;11(8):e0161685
pubmed: 27574974
BMC Res Notes. 2018 Aug 31;11(1):629
pubmed: 30170613
Front Cell Infect Microbiol. 2021 Apr 23;11:601968
pubmed: 33968793